CD8A and neoplasm: Since the major biological activity against tumors in vitro and in vivo displayed by tumor infiltrating lymphocytes (TILs) can be attributed to CD8+ T cells [19], adoptive immunotherapy using in vitro expanded tumor antigen-specific CD8+ CTLs, has been considered as a feasible option for in vivo eradication of tumors [20].